Table 3. Univariate and multivariate Cox analysis of progression free survival and overall survival for bladder cancer patients.
| Parameters | Categories | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| PFS | |||||
| Age | <62 VS ≥62 | 1.189(0.661–2.136) | 0.563 | ||
| Gender | Female VS Male | 0.703(0.369–1.340) | 0.285 | ||
| Grade | G2 VS G3 | 1.542(0.688–3.456) | 0.293 | ||
| T stage | T2 VS T3 VS T4 | 1.664(1.006–2.751) | 0.047 | 1.695(1.050–2.737) | 0.031 |
| Nodal status | Negative VS Positive | 2.645(1.340–5.223) | 0.005 | 2.605(1.309–5.184) | 0.006 |
| Chemotherapy regimens | MVAC VS GC | 1.449(0.747–2.808) | 0.272 | ||
| miR-203 level | Low VS High | 0.143(0.078–0.264) | <0.001 | 0.154(0.082–0.288) | <0.001 |
| OS | |||||
| Age | <62 VS ≥62 | 1.160(0.683–1.970) | 0.583 | ||
| Gender | Female VS Male | 0.861(0.469–1.581) | 0.630 | ||
| Grade | G2 VS G3 | 1.873(0.847–4.142) | 0.121 | ||
| T stage | T2 VS T3 VS T4 | 1.844(1.184–2.874) | 0.007 | 1.800(1.154–2.807) | 0.010 |
| Nodal status | Negative VS Positive | 1.385(0.804–2.388) | 0.241 | ||
| Chemotherapy regimens | MVAC VS GC | 1.516(0.826–2.782) | 0.180 | ||
| miR-203 level | Low VS High | 0.349(0.203–0.600) | <0.001 | 0.359(0.209–0.616) | <0.001 |
Abbreviations: PFS, progression free survival; OS, overall survival; HR, Hazard ratio; CI, Confidence interval